BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26199388)

  • 1. Early Changes in Circulating Tumor Cells Are Associated with Response and Survival Following Treatment of Metastatic Neuroendocrine Neoplasms.
    Khan MS; Kirkwood AA; Tsigani T; Lowe H; Goldstein R; Hartley JA; Caplin ME; Meyer T
    Clin Cancer Res; 2016 Jan; 22(1):79-85. PubMed ID: 26199388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating tumor cells as prognostic markers in neuroendocrine tumors.
    Khan MS; Kirkwood A; Tsigani T; Garcia-Hernandez J; Hartley JA; Caplin ME; Meyer T
    J Clin Oncol; 2013 Jan; 31(3):365-72. PubMed ID: 23248251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Threshold for Circulating Tumor Cells in Patients With Pancreatic and Midgut Neuroendocrine Tumors.
    Mandair D; Khan MS; Lopes A; Furtado O'Mahony L; Ensell L; Lowe H; Hartley JA; Toumpanakis C; Caplin M; Meyer T
    J Clin Endocrinol Metab; 2021 Mar; 106(3):872-882. PubMed ID: 33180939
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum chromogranin-A-based prognosis in metastatic castration-resistant prostate cancer.
    Giridhar KV; Sanhueza C; Hillman DW; Alkhateeb H; Carlson R; Tan W; Costello BA; Quevedo F; Pagliaro L; Kohli M
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):431-437. PubMed ID: 29858590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial.
    Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L
    Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Prognostic Value of Circulating Tumor Cells in Asian Neuroendocrine Tumors.
    Hsieh JC; Chen GY; Jhou DD; Chou WC; Yeh CN; Hwang TL; Lin HC; Chu HC; Wang HM; Yen TC; Chen JS; Wu MH
    Sci Rep; 2019 Dec; 9(1):19917. PubMed ID: 31882775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.
    Goldkorn A; Ely B; Quinn DI; Tangen CM; Fink LM; Xu T; Twardowski P; Van Veldhuizen PJ; Agarwal N; Carducci MA; Monk JP; Datar RH; Garzotto M; Mack PC; Lara P; Higano CS; Hussain M; Thompson IM; Cote RJ; Vogelzang NJ
    J Clin Oncol; 2014 Apr; 32(11):1136-42. PubMed ID: 24616308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.
    Lorente D; Olmos D; Mateo J; Dolling D; Bianchini D; Seed G; Flohr P; Crespo M; Figueiredo I; Miranda S; Scher HI; Terstappen LWMM; de Bono JS
    Ann Oncol; 2018 Jul; 29(7):1554-1560. PubMed ID: 29741566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer.
    Mu Z; Wang C; Ye Z; Rossi G; Sun C; Li L; Zhu Z; Yang H; Cristofanilli M
    Breast Cancer Res Treat; 2017 Oct; 165(3):733-741. PubMed ID: 28687903
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort.
    Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L
    BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biomarker utility of circulating tumor cells in metastatic cutaneous melanoma.
    Khoja L; Lorigan P; Zhou C; Lancashire M; Booth J; Cummings J; Califano R; Clack G; Hughes A; Dive C
    J Invest Dermatol; 2013 Jun; 133(6):1582-90. PubMed ID: 23223143
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients.
    Thalgott M; Rack B; Eiber M; Souvatzoglou M; Heck MM; Kronester C; Andergassen U; Kehl V; Krause BJ; Gschwend JE; Retz M; Nawroth R
    BMC Cancer; 2015 Jun; 15():458. PubMed ID: 26051431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.
    De Laere B; Oeyen S; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; Van Kerckhove P; De Maeseneer D; Strijbos M; Bols A; Fransis K; Beije N; de Kruijff I; van Dam V; Brouwer A; van Dam PJ; Van den Eynden G; Rutten A; Sleijfer S; Vandebroek J; Van Laere S; Dirix L
    Prostate; 2018 May; 78(6):435-445. PubMed ID: 29431193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
    Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
    Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data.
    Bidard FC; Peeters DJ; Fehm T; Nolé F; Gisbert-Criado R; Mavroudis D; Grisanti S; Generali D; Garcia-Saenz JA; Stebbing J; Caldas C; Gazzaniga P; Manso L; Zamarchi R; de Lascoiti AF; De Mattos-Arruda L; Ignatiadis M; Lebofsky R; van Laere SJ; Meier-Stiegen F; Sandri MT; Vidal-Martinez J; Politaki E; Consoli F; Bottini A; Diaz-Rubio E; Krell J; Dawson SJ; Raimondi C; Rutten A; Janni W; Munzone E; Carañana V; Agelaki S; Almici C; Dirix L; Solomayer EF; Zorzino L; Johannes H; Reis-Filho JS; Pantel K; Pierga JY; Michiels S
    Lancet Oncol; 2014 Apr; 15(4):406-14. PubMed ID: 24636208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating Tumor Cell Subtypes and T-cell Populations as Prognostic Biomarkers to Combination Immunotherapy in Patients with Metastatic Genitourinary Cancer.
    Chalfin HJ; Pramparo T; Mortazavi A; Niglio SA; Schonhoft JD; Jendrisak A; Chu YL; Richardson R; Krupa R; Anderson AKL; Wang Y; Dittamore R; Pal SK; Lara PN; Stein MN; Quinn DI; Steinberg SM; Cordes LM; Ley L; Mallek M; Sierra Ortiz O; Costello R; Cadena J; Diaz C; Gulley JL; Dahut WL; Streicher H; Wright JJ; Trepel JB; Bottaro DP; Apolo AB
    Clin Cancer Res; 2021 Mar; 27(5):1391-1398. PubMed ID: 33262136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer.
    Cohen SJ; Punt CJ; Iannotti N; Saidman BH; Sabbath KD; Gabrail NY; Picus J; Morse M; Mitchell E; Miller MC; Doyle GV; Tissing H; Terstappen LW; Meropol NJ
    J Clin Oncol; 2008 Jul; 26(19):3213-21. PubMed ID: 18591556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.
    Huebner H; Fasching PA; Gumbrecht W; Jud S; Rauh C; Matzas M; Paulicka P; Friedrich K; Lux MP; Volz B; Gass P; Häberle L; Meier-Stiegen F; Hartkopf A; Neubauer H; Almstedt K; Beckmann MW; Fehm TN; Ruebner M
    BMC Cancer; 2018 Feb; 18(1):204. PubMed ID: 29463222
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups.
    Lindsay CR; Faugeroux V; Michiels S; Pailler E; Facchinetti F; Ou D; Bluthgen MV; Pannet C; Ngo-Camus M; Bescher G; Caramella C; Billiot F; Remon J; Planchard D; Soria JC; Besse B; Farace F
    Ann Oncol; 2017 Jul; 28(7):1523-1531. PubMed ID: 28633480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor cells in newly diagnosed inflammatory breast cancer.
    Mego M; Giordano A; De Giorgi U; Masuda H; Hsu L; Giuliano M; Fouad TM; Dawood S; Ueno NT; Valero V; Andreopoulou E; Alvarez RH; Woodward WA; Hortobagyi GN; Cristofanilli M; Reuben JM
    Breast Cancer Res; 2015 Jan; 17(1):2. PubMed ID: 25572591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.